(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 55.6MM | -20% |
Gross Profit | 46.9MM | - |
Cost Of Revenue | 8.7MM | -34% |
Operating Income | -8.5MM | -266% |
Operating Expenses | 55.4MM | - |
Net Income | 219K | -98% |
R&D | 14.1MM | +0% |
G&A | 41.3MM | +8% |
Interest Expense | 1.7MM | +0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
While Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders are probably generally happy, the stock hasn't had...
Justin Burgess, the Chief Accounting Officer of Dynavax Technologies Corp (NASDAQ:DVAX), has sold 20,526 shares of the company on March 1, 2024, according to a recent SEC Filing.
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript February 22, 2024 Dynavax Technologies Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and gentlemen and welcome to the Dynavax Technologies’ Fourth Quarter and Full Year 2023 […]
Q4 2023 Dynavax Technologies Corp Earnings Call
DVAX earnings call for the period ending December 31, 2023.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Revenue Growth: HEPLISAV-B net product revenue surged by 69% year-over-year to $213 million in 2023. Market Leadership: Achieved market leader status in retail pharmacy and IDNs, with U.S. market share rising to approximately 42%. 2024 Outlook: HEPLISAV-B net product revenue projected to be $265 - $280 million; company expects to be cash flow positive.
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.